Artículo

Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC)

Fernandez Calotti, Paula; Jordheim, Lars Petter; Giordano, Mirta NildaIcon ; Dumontet, Charles; Galmarini, Carlos Maria
Fecha de publicación: 03/2005
Editorial: Taylor & Francis Ltd
Revista: Leukemia and Lymphoma
ISSN: 1042-8194
Idioma: Inglés
Tipo de recurso: Artículo publicado
Clasificación temática:

Resumen

Acute myelogenous leukemia (AML) is the most common form of acute leukemia in adults. After diagnosis, patients with AML are mainly treated with standard induction chemotherapy combining cytarabine (araC) and anthracyclines. The majority of them achieve complete remission (CR) (65-80%). However, prospects for long-term survival are poor for the majority of patients. Resistance to chemotherapy therefore remains a major obstacle in the effective treatment of patients with AML. In this review, we highlight the current knowledge of substrate cycles involved in normal deoxynucleoside triphosphate (dNTPs) metabolism and their possible role in drug resistance to araC. © 2005 Taylor & Francis Group Ltd.
Palabras clave: Aml , Arac , Nucleotide Metabolism
 
Archivos asociados
Thumbnail
 
Tamaño: 167.7Kb
Formato: PDF
.
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/62580
DOI: https://dx.doi.org/10.1080/10428190400015683
URL: https://www.tandfonline.com/doi/abs/10.1080/10428190400015683
Colecciones
Articulos(IMEX)
Articulos de INST.DE MEDICINA EXPERIMENTAL
Citación
Fernandez Calotti, Paula; Jordheim, Lars Petter; Giordano, Mirta Nilda; Dumontet, Charles; Galmarini, Carlos Maria; Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC); Taylor & Francis Ltd; Leukemia and Lymphoma; 46; 3; 3-2005; 335-346
Compartir
Altmétricas